Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study-Reference-Cited by-同舟云学术

Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

Published:2019-03-12 Issue:1 Volume:5 Page:
ISSN:2055-0294
Container-title:Journal of Pharmaceutical Health Care and Sciences
language:en
Short-container-title:J Pharm Health Care Sci

Author:

Takasaki Shinya,Yamaguchi Hiroaki^ORCID,Kawasaki Yoshihide,Kikuchi Masafumi,Tanaka Masaki,Ito Akihiro,Mano Nariyasu

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology (nursing)

Link

http://link.springer.com/content/pdf/10.1186/s40780-019-0135-5.pdf

Reference29 articles.

1. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney Cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:804–34.

2. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012;30:4017–25.

3. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Leveque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. Eur J Cancer. 2014;50:2020–36.

4. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–58.

5. Tedesco Silva, H., Jr., Cibrik, D., Johnston, T., Lackova, E., Mange, K., Panis, C. et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010;10:1401–1413.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Everolimus prevents doxorubicin-induced apoptosis in H9c2 cardiomyocytes but not in MCF-7 cancer cells: Cardioprotective roles of autophagy, mitophagy, and AKT;Toxicology in Vitro;2023-12

2. Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor;Aging Cell;2023-05-24

3. Everolimus Prevents Doxorubicin-Induced Apoptosis Through Autophagy, Mitophagy and AKT Activation in H9c2 Cardiomyocytes;2023-05-03

4. Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR Inhibitor;2022-12-11

5. Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS;Journal of Chromatography B;2021-05